0
Findings from a phase 1 trial show that an experimental ‘gene silencing’ therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.
Findings from a phase 1 trial show that an experimental ‘gene silencing’ therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.